Lercanidipino Mabo

Lercanidipine hydrochloride, the active ingredient in Lercanidipino Mabo, is a calcium channel blocker presented as a tablet for oral use. It treats essential hypertension in adult patients.

GNH USA supplies Lercanidipino Mabo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine hydrochloride is used to manage blood pressure by targeting the vascular smooth‑muscle calcium pathway. - Essential hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk in adults.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially when standing quickly. - Tiredness: general fatigue. - Palpitations: sensation of rapid heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Angio‑edema: swelling of face, lips, or throat. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, itching, or hives.

Before initiating therapy, consider patient‑specific factors and monitor for potential risks. - Renal impairment: adjust monitoring frequency. - Hepatic disease: evaluate liver function before use. - Concomitant antihypertensives: watch for additive blood‑pressure lowering. - Elderly patients: start at low dose and titrate cautiously. - Pregnancy and lactation: avoid unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of hypotension. - Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood‑pressure reduction. - Simvastatin or other statins metabolized by CYP3A4: monitor for myopathy. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.